Multiple myeloma is the second most common hematological neoplasm and despite therapeutic advances over the last ten years, it remains incurable for most patients. It is a unique cancer model used to research mechanisms that regulate malignant transformation from a benign stage called "monoclonal gammopathy of undetermined significance (MGUS)" to an indolent stage that progresses to a more advanced and active form of the disease: symptomatic multiple myeloma.
Multiple myeloma is a singular model in that different clinical stages have a common denominator: the clonal plasma cell. This same common denominator is shared with other monoclonal gammopathies such as primary systemic amyloidosis and is characterized by the spread of a small clone of aberrant plasma cells.
Our line of research is cross-sectional between multiple myeloma and other monoclonal gammopathies. It has the following objectives:
1. Characterization of the tumor cell based on preclinical models and clinical trials and identification of resistance biomarkers and potential therapeutic targets.
2. Application of ultra-sensitive methods for monitoring minimal residual disease.
3. Characterization of primary systemic amyloidosis, clinical manifestations and disease prognosis.
Fecha de actualización: Junio 2019
"One of our areas of research focuses on identifying resistance biomarkers and potential therapeutic targets for multiple myeloma", Dr. Jesús San Miguel, Principal Investigator.